Literature DB >> 20306312

Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer.

Mansooreh Jaberipour1, Mojtaba Habibagahi, Ahmad Hosseini, Saadat Rezai Habibabad, Abdolrasoul Talei, Abbas Ghaderi.   

Abstract

Generation of Regulatory T cells (Tregs) is known to play a major role in progression and modulation of the immune escape mechanisms in cancer. These cells express Forkhead/winged helix transcription factor (FOXP3) and also Cytotoxic T-lymphocyte antigen-4 (CTLA-4), as a negative regulatory molecule which, is a potential target for immunotherapy. We, therefore, evaluated FOXP3 and CTLA-4 transcripts in the peripheral blood mononuclear cells from 55 women with histologically-confirmed infiltrating ductal carcinoma of the breast. Blood samples from 40 healthy volunteer women without a history of malignancies or autoimmune disorders were also obtained as a control. The abundance of FOXP3 and CTLA-4 gene transcripts was determined by quantitative real-time PCR (qRT-PCR). Compared to healthy individuals, significantly higher amounts of these transcripts were found in the mononuclear cells from breast cancer patients. Also, a significant correlation was found between CTLA-4 and FOXP3 expressions in a group of patients. Among patients with early stage, nonmetastatic or low-grade disease, the relative expression of CTLA-4 was about 10-fold as much as in the control group. These patients also showed a significant increase, more than 10 fold, in mean relative FOXP3 expression. The results of this investigation point to functional activity of Treg cells in early stages of breast cancer, a finding which emphasizes the significance of Tregs as an imminent target for breast cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20306312     DOI: 10.1007/s12253-010-9256-8

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  33 in total

Review 1.  Assessing the in vitro suppressive capacity of regulatory T cells.

Authors:  Todd M Brusko; Maigan A Hulme; Courtney B Myhr; Michael J Haller; Mark A Atkinson
Journal:  Immunol Invest       Date:  2007       Impact factor: 3.657

2.  [Expressions of Fas, CTLA-4 and RhoBTB2 genes in breast carcinoma and their relationship with clinicopathological factors].

Authors:  Ye Bi; Ling Wei; Hai-ting Mao; Ling Zhang; Wen-shu Zuo
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2008-10

3.  Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.

Authors:  Sebastian Tuve; Bing-Mae Chen; Ying Liu; Tian-Lu Cheng; Papa Touré; Papa Salif Sow; Qinghua Feng; Nancy Kiviat; Robert Strauss; Shaoheng Ni; Zong-Yi Li; Steve R Roffler; André Lieber
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

4.  Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells.

Authors:  Manuelle Viguier; Fabrice Lemaître; Olivier Verola; Min-Sun Cho; Guy Gorochov; Louis Dubertret; Hervé Bachelez; Philippe Kourilsky; Laurent Ferradini
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

Review 5.  Regulatory T cells and tumour immunity - observations in mice and men.

Authors:  Awen Gallimore; Andrew Godkin
Journal:  Immunology       Date:  2007-12-07       Impact factor: 7.397

6.  Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis.

Authors:  Sachin Gupta; Kusum Joshi; J D Wig; Sunil K Arora
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

7.  Evidence for immune defects in breast and lung cancer patients.

Authors:  Iuliana Caras; A Grigorescu; Crina Stavaru; D L Radu; I Mogos; G Szegli; Aurora Salageanu
Journal:  Cancer Immunol Immunother       Date:  2004-12       Impact factor: 6.968

Review 8.  Type 1 T regulatory cells and their relationship with CD4+CD25+ T regulatory cells.

Authors:  Maria Grazia Roncarolo; Silvia Gregori; Megan Levings
Journal:  Novartis Found Symp       Date:  2003

9.  Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma.

Authors:  Kazuo Matsuura; Yoshiyuki Yamaguchi; Hideaki Ueno; Akihiko Osaki; Koji Arihiro; Tetsuya Toge
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860

10.  FOXP3 expression and overall survival in breast cancer.

Authors:  Andrea Merlo; Patrizia Casalini; Maria Luisa Carcangiu; Chiara Malventano; Tiziana Triulzi; Sylvie Mènard; Elda Tagliabue; Andrea Balsari
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

View more
  15 in total

1.  A novel potential effective strategy for enhancing the antitumor immune response in breast cancer patients using a viable cancer cell-dendritic cell-based vaccine.

Authors:  Mona S Abdellateif; Sabry M Shaarawy; Eman Z Kandeel; Ahmed H El-Habashy; Mohamed L Salem; Motawa E El-Houseini
Journal:  Oncol Lett       Date:  2018-05-04       Impact factor: 2.967

Review 2.  T cell coinhibition and immunotherapy in human breast cancer.

Authors:  Murali Janakiram; Yael M Abadi; Joseph A Sparano; Xingxing Zang
Journal:  Discov Med       Date:  2012-10       Impact factor: 2.970

3.  Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis.

Authors:  Haiming Yu; Junlan Yang; Shunchang Jiao; Ying Li; Wei Zhang; Jiandong Wang
Journal:  Cancer Immunol Immunother       Date:  2015-04-17       Impact factor: 6.968

4.  The expression levels of transcription factors T-bet, GATA-3, RORγt and FOXP3 in peripheral blood lymphocyte (PBL) of patients with liver cancer and their significance.

Authors:  Ze-Wei Lin; Li-Xuan Wu; Yong Xie; Xi Ou; Pei-Kai Tian; Xiao-Ping Liu; Jun Min; Jie Wang; Ru-Fu Chen; Ya-Jing Chen; Chao Liu; Hua Ye; Qing-Jia Ou
Journal:  Int J Med Sci       Date:  2015-01-01       Impact factor: 3.738

5.  Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma.

Authors:  Michihito Tagawa; Naoya Maekawa; Satoru Konnai; Satoshi Takagi
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

6.  The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.

Authors:  Qing-Kun Song; Jun Ren; Xin-Na Zhou; Xiao-Li Wang; Guo-Hong Song; Li-Jun Di; Jing Yu; Amy Hobeika; Michael A Morse; Yan-Hua Yuan; Hua-Bing Yang; Herbert Kim Lyerly
Journal:  Oncotarget       Date:  2015-12-01

7.  Enhanced Suppressive Activity of Regulatory T Cells in the Microenvironment of Malignant Pleural Effusions.

Authors:  Joanna Budna; Mariusz Kaczmarek; Agata Kolecka-Bednarczyk; Łukasz Spychalski; Piotr Zawierucha; Joanna Goździk-Spychalska; Michał Nowicki; Halina Batura-Gabryel; Jan Sikora
Journal:  J Immunol Res       Date:  2018-03-26       Impact factor: 4.818

8.  Immunologic targeting of FOXP3 in inflammatory breast cancer cells.

Authors:  Smita Nair; Amy J Aldrich; Eoin McDonnell; Qing Cheng; Anshu Aggarwal; Pujan Patel; Monique M Williams; David Boczkowski; H Kim Lyerly; Michael A Morse; Gayathri R Devi
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

9.  Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC.

Authors:  Chandan Verma; Jennifer M Eremin; Adrian Robins; Andrew J Bennett; Gerard P Cowley; Mohamed A El-Sheemy; Jibril A Jibril; Oleg Eremin
Journal:  J Transl Med       Date:  2013-01-15       Impact factor: 5.531

10.  Expression of CTLA-4 and Foxp3 in peripheral blood T cells of patients with squamous cell laryngeal carcinoma.

Authors:  Katarzyna Starska; Ewa Forma; Iwona Lewy-Trenda; Jan Woś; Paweł Papież; Marcin Mochocki; Piotr Morawski; Renata Kopta; Magdalena Bryś
Journal:  Contemp Oncol (Pozn)       Date:  2013-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.